Physician profile
Benjamin Wolcott
NPI 1467890822
$3,134.60
in general payments reported to CMS, 2019-2025
18 companies · $573 in 2025
The $573 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $132 · 2021: $264 · 2022: $313 · 2023: $485 · 2024: $1,168 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,480.19 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $469.03 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $234.91 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $202.89 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $180.74 | 2019-2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $154.07 | 2019-2022 | |
| Pfizer INC. | $118.11 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $80.35 | 2025 | Jornay Pm |
| Genentech USA, INC. | $48.94 | 2022-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $28.18 | 2025 | Neffy |
| Sanofi Pasteur INC. | $26.73 | 2025 | |
| Aimmune Therapeutics, INC. | $17.43 | 2023 | |
| Kaleo, INC. | $17.29 | 2019 | |
| Merck Sharp & Dohme LLC | $16.84 | 2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Arbor Pharmaceuticals, INC. | $16.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $15.49 | 2021 | |
| Seqirus USA INC | $13.91 | 2025 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $13.35 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wolcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.